BR112019002729A2 - composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida - Google Patents

composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida

Info

Publication number
BR112019002729A2
BR112019002729A2 BR112019002729-7A BR112019002729A BR112019002729A2 BR 112019002729 A2 BR112019002729 A2 BR 112019002729A2 BR 112019002729 A BR112019002729 A BR 112019002729A BR 112019002729 A2 BR112019002729 A2 BR 112019002729A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
solid pharmaceutical
preparing
solid
composition
Prior art date
Application number
BR112019002729-7A
Other languages
English (en)
Inventor
Seminara Stefano
Tajchert Agnieszka
Schwarz Franz
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of BR112019002729A2 publication Critical patent/BR112019002729A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Abstract

composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida
BR112019002729-7A 2016-08-12 2017-08-09 composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida BR112019002729A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16184053 2016-08-12
EP16184053.3 2016-08-12
PCT/EP2017/070215 WO2018029262A1 (en) 2016-08-12 2017-08-09 Solid pharmaceutical composition comprising amorphous sofosbuvir

Publications (1)

Publication Number Publication Date
BR112019002729A2 true BR112019002729A2 (pt) 2019-05-14

Family

ID=56684527

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002729-7A BR112019002729A2 (pt) 2016-08-12 2017-08-09 composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida

Country Status (11)

Country Link
US (1) US20190167706A1 (pt)
EP (1) EP3496705A1 (pt)
JP (1) JP2019530645A (pt)
KR (1) KR20190038881A (pt)
CN (1) CN109862884A (pt)
AU (1) AU2017309302A1 (pt)
BR (1) BR112019002729A2 (pt)
CA (1) CA3033319A1 (pt)
MX (1) MX2019001771A (pt)
RU (1) RU2019106294A (pt)
WO (1) WO2018029262A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214711A (zh) * 2019-06-28 2019-09-10 昱庆塑胶五金制品（惠州）有限公司 智能宠物喂食器
CN111467363A (zh) * 2020-04-07 2020-07-31 中国科学院深圳先进技术研究院 索非布韦在制备预防和治疗冠状病毒的药物中的应用
CN111773192A (zh) * 2020-08-18 2020-10-16 福建广生堂药业股份有限公司 一种索磷布韦片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
EP2907505A3 (en) 2011-12-29 2015-12-30 Abbvie Inc. Solid compositions comprising an HCV inhibitor
WO2015132321A1 (en) * 2014-03-05 2015-09-11 Galenicum Health S.L. Stable pharmaceutical compositions of sofosbuvir
CA2943574A1 (en) * 2014-04-03 2015-10-08 Sandoz Ag Solid composition comprising amorphous sofosbuvir
WO2016038542A2 (en) * 2014-09-10 2016-03-17 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物

Also Published As

Publication number Publication date
CA3033319A1 (en) 2018-02-15
WO2018029262A1 (en) 2018-02-15
MX2019001771A (es) 2019-11-18
JP2019530645A (ja) 2019-10-24
EP3496705A1 (en) 2019-06-19
CN109862884A (zh) 2019-06-07
AU2017309302A1 (en) 2019-02-21
US20190167706A1 (en) 2019-06-06
KR20190038881A (ko) 2019-04-09
RU2019106294A (ru) 2020-09-21

Similar Documents

Publication Publication Date Title
ECSP18008905A (es) Tricíclicos sustituidos y método para usarlos.
GEP20217239B (en) Pharmaceutical composition
CR20180564A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que lo contienen
BR112018000729A2 (pt) métodos e composições para o aprimoramento de traços de plantas
DK3529248T3 (da) Farmaceutiske sammensætninger
BR112018006696A2 (pt) métodos e sistemas para obter óleo a partir de uma composição de vinhoto
BR112016021682A2 (pt) cenicriviroc para o tratamento da fibrose
BR112018004056A2 (pt) material hemostático, método para produzir um material hemostático, e, kit
BR112017025427A2 (pt) composição farmacêutica oral
GEP20217240B (en) Pharmaceutical composition
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
FI20155621A (fi) Menetelmä ja tuote
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
MA47516A (fr) Composition pharmaceutique
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
BR112019002729A2 (pt) composição farmacêutica sólida e processo para preparar uma composição farmacêutica sólida
BR112017008097A2 (pt) método para tratar condições oculares
BR112017017883A2 (pt) doses e métodos para administrar telavancina
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
KR102374939B9 (ko) 경화성 조성물, 경화물 및 경화물의 제조 방법
IT201700016964A1 (it) Composizione per la tosse
BR112016026684A2 (pt) Fertilizante à base de enxofre
FI20155729A (fi) Menetelmä ja tuote
DK3089740T3 (da) Farmaceutisk sammensætning

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]